{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:09Z","timestamp":1790686209402,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"am","delay-in-days":437,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.lpm.2019.07.020","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T17:34:33Z","timestamp":1566322473000},"page":"832-841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["Maladie de Waldenstr\u00f6m"],"prefix":"10.1016","volume":"48","author":[{"given":"C\u00e9cile","family":"Tomowiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Debiais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lpm.2019.07.020_bib0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstr\u00f6m macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.lpm.2019.07.020_bib0160","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term-follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2019.07.020_bib0165","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdj111","article-title":"Characterization of familial Waldenstr\u00f6m's macroglobulinemia","volume":"17","author":"Treon","year":"2006","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2019.07.020_bib0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jnci\/djq043","article-title":"Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstr\u00f6m macroglobulinemia","volume":"102","author":"Kristinsson","year":"2010","journal-title":"J Nat Cancer Inst"},{"issue":"1","key":"10.1016\/j.lpm.2019.07.020_bib0175","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1529-8027.2012.00376.x","article-title":"Heterogeneous spectrum of neuropathies in Waldenstr\u00f6m's macroglobulinemia: a diagnostic strategy to optimize their management","volume":"17","author":"Viala","year":"2012","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10.1016\/j.lpm.2019.07.020_bib0180","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/all.12129","article-title":"Schnitzler's syndrome: diagnosis, treatment, and follow-up","volume":"68","author":"Simon","year":"2013","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.lpm.2019.07.020_bib0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth international workshop","volume":"160","author":"Owen","year":"2013","journal-title":"B J Haematol"},{"issue":"4","key":"10.1016\/j.lpm.2019.07.020_bib0190","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.14279","article-title":"Renal disease related to Waldenstr\u00f6m macroglobulinaemia: incidence, pathology and clinical outcomes","volume":"175","author":"Vos","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.lpm.2019.07.020_bib0195","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bjh.13078","article-title":"MYD88\u00a0L265P mutation contributes to the diagnosis of Bing Neel syndrome","volume":"167","author":"Poulain","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.lpm.2019.07.020_bib0200","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3324\/haematol.2016.147728","article-title":"Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome","volume":"102","author":"Minnema","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.lpm.2019.07.020_bib0205","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1158\/1078-0432.CCR-10-2954","article-title":"The role of serum immunoglobulin free light chain in response and progression in Waldenstr\u00f6m macroglobulinemia","volume":"17","author":"Leleu","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.lpm.2019.07.020_bib0210","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174\u00a0untreated patients with Waldenstr\u00f6m's macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.lpm.2019.07.020_bib0215","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.14881","article-title":"Transformed Waldenstr\u00f6m macroglobulinaemia: clinical presentation and outcome. A multiinstitutional retrospective study of 77\u00a0cases from the French Innovative Leukemia Organization (FILO)","volume":"179","author":"Durot","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.lpm.2019.07.020_bib0220","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.14386","article-title":"MYD88\u00a0mutations can be used to identify malignant pleural effusions in Waldenstr\u00f6m macroglobulinaemia","volume":"180","author":"Gustine","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.lpm.2019.07.020_bib0225","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88\u00a0L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.lpm.2019.07.020_bib0230","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53\u00a0mutation and its prognostic significance in Waldenstr\u00f6m's macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.lpm.2019.07.020_bib0235","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","article-title":"Genomic landscape of CXCR4\u00a0mutations in Waldenstr\u00f6m macroglobulinemia","volume":"22","author":"Poulain","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.lpm.2019.07.020_bib0240","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88\u00a0wild-type Waldenstr\u00f6m macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br J Haematol"},{"issue":"27","key":"10.1016\/j.lpm.2019.07.020_bib0245","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.lpm.2019.07.020_bib0250","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"iNNOVATE study group and the european consortium for Waldenstr\u00f6m's macroglobulinemia. Phase 3\u00a0trial of ibrutinib plus rituximab in Waldenstr\u00f6m's macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.lpm.2019.07.020_bib0255","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lpm.2019.07.020_bib0260","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstr\u00f6m's macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.lpm.2019.07.020_bib0265","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: final analysis of a phase 2\u00a0study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.lpm.2019.07.020_bib0270","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3\u00a0non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.lpm.2019.07.020_bib0275","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood-2008-09-177329","article-title":"Long-term outcomes to fludarabine and rituximab in Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Treon","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lpm.2019.07.020_bib0280","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.lpm.2019.07.020_bib0285","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","article-title":"BDR in newly diagnosed patients with WM: final analysis of a phase 2\u00a0study after a minimum follow-up of 6\u00a0years","volume":"129","author":"Gavriatopoulou","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.lpm.2019.07.020_bib0290","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Eng J Med"},{"issue":"2","key":"10.1016\/j.lpm.2019.07.020_bib0295","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3\u00a0trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.lpm.2019.07.020_bib0150","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bjh.15202","article-title":"How we manage patients with Waldenstr\u00f6m macroglobulinaemia","volume":"181","author":"Simon","year":"2018","journal-title":"Br J Haematol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219303100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219303100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:04:55Z","timestamp":1760105095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498219303100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":30,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0755498219303100"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2019.07.020","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maladie de Waldenstr\u00f6m","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2019.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}